[Efficiency of rituximab in acquired hemophilia: report of two cases and review of literature]

A Millet; O Decaux; B Bareau; B Guillet; C Cazalets; A Perlat; P Jego; B Grosbois

doi:10.1016/j.revmed.2007.06.017

[Efficiency of rituximab in acquired hemophilia: report of two cases and review of literature]

Rev Med Interne. 2007 Dec;28(12):862-5. doi: 10.1016/j.revmed.2007.06.017. Epub 2007 Jul 25.

[Article in French]

Authors

A Millet¹, O Decaux, B Bareau, B Guillet, C Cazalets, A Perlat, P Jego, B Grosbois

Affiliation

¹ Service de médecine interne, département de médecine de l'adulte, hôpital Sud, 16, boulevard de Bulgarie, 35203 Rennes cedex 02, France.

PMID: 17707554
DOI: 10.1016/j.revmed.2007.06.017

Abstract

Introduction: Acquired hemophilia due to an inhibitor of factor VIII is a rare clinical situation.

Exegesis: Rituximab is now used in the treatment of acquired hemophilia. We report two cases of acquired hemophilia treated by rituximab with efficiency.

Conclusion: Rituximab appears to be a first line immunosuppressive therapy in acquired hemophilia, especially in post-partum hemophilia.

Publication types

Case Reports
English Abstract

MeSH terms

Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Factor VIII / metabolism
Female
Hemophilia A / drug therapy*
Humans
Immunologic Factors / therapeutic use*
Rituximab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab
Factor VIII